Fundraising FoxNEA Secondary
Venture capitalTimonium · 7 people tracked
Find your way into NEA Secondary
Each arrow is one introduction. Sign up to fill in the first one.
Ask Josh Wolfe to introduce you to Ali Behbahani
You →Josh · together at Genocea Biosciences →Ali
Ask Jamie Chen to introduce you to Rick Yang
You →Jamie · together at Plaid →Rick
Ask Sam Okafor to introduce you to Mohamad H. Makhzoumi
You →Sam · together at Waymark →Mohamad
- Edward T. Mathers5 people can intro you
Sign up to find every way you can get introduced to NEA Secondary
- Your email: who you already know at NEA Secondary, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the NEA Secondary team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Fund manager profile
NEA Secondary is a venture fund manager based in Timonium. SEC filings show 1 venture fund on record, most recently NEA Secondary Opportunity Fund, L.P. ($468.2M offering) filed July 2024.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 7 people
from public directoriesWhat they invest in
from 8 of 8 portfolio companiesBiotech ×6Healthtech ×4AI & Machine Learning ×2Deep Tech ×2Medical Devices ×2Digital Health ×1
HQs:United States×8
Investments · 8 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 22023 · 22022 · 12021 · 18 dated
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYvonne Li(Executive Officer)inJames Collins(Director)
BoardDonald Tang(Director)
Board seatEdward Mathers· per SEC Form D · $40M raise · filed Jun 2026
Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLifeSci Venture PartnersLux CapitalMenlo Ventures+12 more
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)
Board seatEdward Mathers· per SEC Form D · $45M raise · filed Oct 2025
Co-investorsAtlas VentureEcoR1 CapitalEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)+1 more
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Board seatAli Behbahani· per SEC Form D · $100M raise · filed Feb 2023
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+5 more
HealthtechForest Lake, US
Steve Goedeke(Executive Officer, Director)
BoardKaren Shanahan(Director)William Abraham(Director)Michael DeMane(Director)Jay Graf(Director)
Board seatAli Behbahani· per SEC Form D · $11.5M raise · filed Oct 2021
Co-investorsAscension VenturesNew Enterprise Associates (NEA)
Sorriso Pharma is a biopharmaceutical company backed by leading venture capital firms specializing in life sciences and healthcare investments.
BiotechHealthtechMedical DevicesSandy, US
Ciara Kennedy, Ph.D.(Executive Officer, Director)Brian Dorsey(Executive Officer)Michael Grey(Director)Mark Chin(Director)Susan Dube(Executive Officer)
Board seatEdward Mathers· per SEC Form D · $31.4M raise · filed Jan 2022
Co-investorsNew Enterprise Associates (NEA)Pappas Capital
Waymark builds an AI-powered clinic model for Medicaid populations, using predictive analytics and clinical decision support to identify at-risk patients and coordinate community-based care.
AI & Machine LearningDigital HealthHealthtechSan Francisco, US
Afia Asamoah(Co-Founder and Head of People and Legal)inSanjay Basu(Co-Founder and Head of Clinical)inRajaie Batniji(Co-Founder and CEO)inRajaie Batniji MD DPhil(Founder)inSanjay Basu, MD, PhD(Founder)inKelly Coffin(Executive Officer, Director, Promoter)
Board seatMohamad Makhzoumi· per SEC Form D · $22M raise · filed Nov 2023
Co-investorsAcumen AmericaAndreessen HorowitzCVS Health VenturesLux CapitalNew Enterprise Associates (NEA)Twine Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
1 IPOsSenti BiosciencesNASDAQ: SNTI
Portfolio news
latest coverage across their companiesAffinia Therapeutics · finsmes.com · Oct 8, 2025
Frequently asked questions
- How many investments has NEA Secondary made?
- NEA Secondary has 8 tracked investments, 1 of which have exited, including 2 dated in the last 24 months.
- Where is NEA Secondary located?
- NEA Secondary is headquartered in Timonium, US.